Archive | Fundraising RSS feed for this section

Introducing RESI AI and RESI Longevity

22 Apr

By Caitlin Dolegowski, Marketing Specialist, LSN


Life Science Nation (LSN) renames its two newest conferences under the Redefining Early Stage Investments (RESI) banner. This conference series has provided early-stage life science entrepreneurs a space dedicated to their fundraising efforts through connecting them with partners and capital that are a fit for their product and stage of development. Through the years, LSN has worked with thousands of executives in their search for partnerships, and the secret has always been that it all comes down to finding that right fit. In order to help target these elusive matches, LSN spun two sister conferences, 4D Meets AI and Longevity, Health and Innovation, now RESI AI and RESI Longevity respectively, out of the RESI conference series, designed to further narrow down the early-stage life science players, based on technology and indication.

4D Meets AI has focused on connecting entrepreneurs using AI technology to advance drugs, devices, diagnostics, and digital health (4Ds) with investors and partners actively seeking AI applications in their themes and portfolios. Longevity, Health & Innovation, co-organized with Mary Furlong & Associates, is a space for fundraising executives targeting diseases that disproportionately affect aging populations to connect with capital and resources specifically in age-tech.

These two conferences are designed to create a more intimate atmosphere within the RESI partnering ecosystem. Each invites a unique attendee, yet both are a digital partnering conferences advancing the mission of the RESI series – to connect technology in life science and health care with well-fitting capital and channel partners – which is why they return this fall as RESI AI and RESI Longevity.

RESI Longevity and RESI AI both take place September 16-17 as two-day digital partnering conferences. Each will feature their own unique lineups of Investor Panels, Educational Workshops, Innovator’s Pitch Challenges and Premier Partnering Platforms. Learn more about each conference and sign up by July 23 to save $100 on super early bird prices!

Timing and Relationship: The Key to Compelling Investor Mandates

8 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

As the life science arena shifts, so do investment and licensing mandates and the technologies that investors and strategic partners seek. Life Science Nation (LSN) is known for its curated partnering database for fundraising early-stage companies across the silos of drugs, devices, diagnostics and digital health. This database has ten categories of investors ranging from angel groups and family offices to VCs, PEs, Big Pharma/Medtech, foundations and the non-dilutive federal, state and regional agencies.

The LSN mantra to healthcare scientist-entrepreneurs and fundraising CEOs is that partnering is a numbers game, and that getting a Global Target List (GTL) of potential partners that are a fit for your stage of development and product set is a crucial step to a successful fundraising campaign. Furthermore, it’s essential to canvass outside your region, engaging global partners to maximize the likelihood of building a relationship that could secure a partnership. 

The LSN Investor Research Team curates the LSN Investor Database, which consists of profiles that fundraising clients can access with an annual subscription. Tools like the database are essential aids for success in a global fundraising campaign. The database features more than ten thousand investor contacts representing several thousand funding and licensing firms. The team’s goal is to keep all the partnering mandates updated in order to ensure the best fit, and this is done through bi-annual interviews. 

These firms are willing to be part of the LSN Investor Platform because we provide them with quality deal-flow, companies that know they are a fit for the firm’s investment theme or partnering interests. Additionally, each year, five Redefining Ealy Stage Investments (RESI) partnering events attract the who’s-who of early-stage life science investing and give them another avenue to connect with fundraising companies that match their interests. These conferences consist of investor panels, workshops, and matched partnering meetings, taking advantage of the profiles the investor research team gathers and the long-term relationships we build while keeping their mandates current.  

The relationship between LSN and the global investor community is deep and has helped hundreds of companies get funded by connecting with investors and partners. Just this week, the Investor Research Team has updated over forty-five mandates, facilitating super fresh profile updates for LSN clients seeking funding. Check out this week’s investor mandates and reach out to your LSN business development representative to view these investors and learn how to get plugged into the LSN partnering ecosystem.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada 
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Ashley Zborowski
Director of Business Development
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!

Keep the Conversations Going

18 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

Healthtech Partnering Week is off to the races! Digital RESI March has wrapped up with 1,000+ meetings in 3 days and leads into a triple-threat partnering experience consisting of 4D Meets AI, Access China Spring Forum (free), and Longevity, Health & Innovation taking place consecutively March 18-19.

It’s not too late to sign up and get involved in any of these three events! To learn more, visit the Healthtech Partnering Week website. Each conference offers unique opportunities suited for specific technology assets and market solutions. We hope you’ll join us and round out your RESI partnering with the full Healthtech Partnering Week experience!

Introducing Healthtech Partnering Week Innovator’s Pitch Challenge Finalists

11 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireLife Science Nation (LSN) is pleased to announce next week’s Healthtech Partnering Week (HPW) Innovator’s Pitch Challenge finalists. The Innovator’s Pitch Challenge is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session.

Pitching opportunities at LSN partnering events are popular events for startups and investors alike. They provide exposure and experience to the companies, while providing investors with insight into the latest technology organized by sector and interest. Check out our finalists and select a logo to learn more about their participation. Registration is still open, so don’t miss out and sign up today!

Innovator’s Pitch Challenge Finalists


Announcing McDermott Will & Emery HPW Workshops

11 Mar

By Gregory Mannix, Vice President International Business Development, LSN

Life Science Nation (LSN) is thrilled to welcome McDermott Will & Emery as Title Sponsor of Healthtech Partnering Week (HPW) with two live workshops accessible to registered attendees of Redefining Early Stage Investments (RESI) and 4D Meets AI.

McDermott Will & Emery has brought valuable insights to LSN’s community of early-stage fundraising companies, investors, service providers, and strategic partnerships for years, and we look forward to bringing their content to the digital stage next week. There’s still time to register for HPW – Sign up for access to McDermott Will & Emery workshops and more!

Negotiating Term Sheets: What’s Best for the Company and What’s Best for You?
Live Workshop! March 16 | 1 PM EDT (Register for RESI Access)


  • Nancy Briefs, President & CEO, AltrixBio, Inc.
  • David Hendren, Managing Director, Augmentum Ventures
  • Mark Mihanovic, Partner, McDermott Will & Emery
  • Aroma Sharma, Partner, McDermott Will & Emery

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion. Learn more!

How to Go to Market: Commercializing AI-Based Health Technologies
Live Workshop! March 19 | 10 AM EDT (Register for 4D Meets AI Access)


  • Richie Bavasso, MBA, Co-Founder & CEO, nQ Medical Inc.
  • Carolyn Metnick, JD, Partner, McDermott Will & Emery
  • Michael Ryan, JD, Partner, McDermott Will & Emery
  • Dale Van Demark, JD, Partner, McDermott Will & Emery

This workshop, hosted by our Title Sponsor McDermott Will & Emery, will focus on the various options for and the legal considerations involved with commercializing AI-based healthcare technologies, including regulatory and data strategies. Learn about the range of options, from R&D use to consumer products, from leading members of McDermott’s digital health practice and companies that have blazed the trail. Learn more!

NVIDIA Spotlights Drug Discovery AI Startups at 4D Meets AI

11 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

NVIDIA Global Healthcare AI Startups Lead, Renee Yao is shining a spotlight on exceptional AI startups using their technology to advance drug discovery. This startup showcase will feature leaders from three AI companies – Entos, Insilico Medicine, and nference – at next week’s 4D Meets AI digital partnering conference.

The startups showcase complements the mission of 4D Meets AI in its goal of highlighting exceptional AI technology and its applications in advancing healthcare. 4D Meets AI promotes and facilitates conversations that lead to deals funding the future of AI technology improving medical care and overall health for future generations.

There’s still time to sign up for 4D Meets AI, March 18-19. If you’re fundraising for your AI technology, you don’t want to miss this partnering experience! Check out NVIDIA’s startup showcase and sign up to start meeting with early-stage companies, investors, service providers, and strategic partners advancing AI technology for health and wellness.

NVIDIA Inception Drug Discovery AI Startup Showcase
Moderator: Renee Yao, Global Healthcare AI Startups Lead, NVIDIA
Pharma companies’ overall venture investments have grown steadily over the last 5 years — but AI has emerged as a standout area of investment, with pharma incumbent-backed healthcare AI funding growing more than 10x since 2018. In this talk, you will hear about NVIDIA inception program benefits for healthcare AI startups and hear about a few cutting-edge drug discovery AI startups’ latest breakthroughs.

Accelerating Molecular Discovery through GPU-Enabled Physics-Based Machine Learning
Tom Miller, PhD, CEO, Entos, Inc.

GPU-Enabled Generative Biology and Generative Chemistry for End-to-End Drug Discovery
Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine

nference: Making Biomedical Knowledge Computable
Tyler Wagner, PhD, Senior Director, Biomedical Research, nference

Speaker Bios

Renee Yao, Global Healthcare AI Startups Lead, NVIDIA (Moderator)
Renee Yao leads global healthcare AI startups at NVIDIA, managing 1000+ healthcare startups in digital health, medical instrument, medical imaging, genomics, and drug discovery segments. Previously she worked as a senior product manager and product marketing manager for AI Systems at NVIDIA.

Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (, a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe’s largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Tom Miller, PhD, CEO, Entos, Inc.

Tom Miller is a scientist and entrepreneur with a focus on AI-driven methods for molecular simulation and discovery. Following a PhD at Oxford and a postdoc at UC Berkeley, he joined the Caltech faculty in 2008 and was promoted to full professor in 2013. He has published more than 120 peer-reviewed articles and received awards for research excellence from the Sloan Foundation, Dreyfus Foundation, and American Chemical Society. He has mentored dozens of students and postdocs that are now leaders in academics and industry. In 2020, Tom co-founded Entos, Inc. to accelerate molecular and materials discovery via physics-based machine learning. In the past year, Entos has recruited over 25 world-class AI researchers, software engineers, and drug discovery scientists and continues to grow.

Tyler Wagner, PhD, Senior Director, Biomedical Research, nference
Dr. Tyler Wagner is the Senior Director of Biomedical Research at nference and has been with the company for over 3 years. Prior to joining nference, Dr. Wagner obtained his PhD in the Weiss lab (MIT) and Densmore lab (BU) where he engineered both an RNA virus and mRNA into multi-functional platforms for regulated gene delivery. He continued with a postdoc in the Weiss lab where he explored in vivo regulatory strategies for RNA therapeutics. At nference, he is currently leading clinical research projects with multiple pharma companies and the Mayo Clinic, ranging from early detection of disease to real-world outcomes assessment, and is working to apply machine learning to outstanding questions in multiple therapeutic areas, including cardiology, oncology, and neuroscience.

Got a Moment for a Great Match?

4 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireHealthtech Partnering Week (HPW) launches in just over a week, and the team at Life Science Nation (LSN) is proud to welcome 400+ investors to our digital platform to source portfolio assets across life science and healthcare. LSN works with exceptional early-stage companies to connect them with investors and strategic partners that are a fit for their product and stage of development, and one of the most powerful ways that is done is through digital partnering events where attendees can filter through hundreds of opportunities and find the best fits for their needs.

Check out our current list of confirmed investors and sign up to begin booking meetings and making deals!

Confirmed Digital RESI March Investors and Strategic Partners

Confirmed RESI Investors Confirmed 4D Meets AI Investors Confirmed LHI Investors

%d bloggers like this: